Thermo Fisher Scientific (NYSE:TMO) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of Thermo Fisher Scientific (NYSE:TMO) from a buy rating to a hold rating in a research report released on Saturday.

TMO has been the subject of several other reports. DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 target price for the company. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday. Finally, UBS Group reaffirmed a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $619.65.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $464.64 on Friday. The firm has a 50 day moving average of $493.53 and a 200 day moving average of $546.70. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $172.67 billion, a price-to-earnings ratio of 25.54, a price-to-earnings-growth ratio of 2.06 and a beta of 0.88. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts anticipate that Thermo Fisher Scientific will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were issued a dividend of $0.47 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 5,800 shares of company stock worth $2,963,544 in the last three months. Insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several large investors have recently bought and sold shares of the business. Oslo Pensjonsforsikring AS bought a new stake in Thermo Fisher Scientific in the first quarter worth $886,000. HORAN Wealth LLC increased its position in Thermo Fisher Scientific by 107.8% in the first quarter. HORAN Wealth LLC now owns 14,028 shares of the medical research company’s stock worth $6,989,000 after purchasing an additional 7,278 shares during the last quarter. Andra AP fonden increased its position in Thermo Fisher Scientific by 1,411.9% in the first quarter. Andra AP fonden now owns 57,814 shares of the medical research company’s stock worth $28,417,000 after purchasing an additional 53,990 shares during the last quarter. Wilkerson Advisory Group LLC increased its position in Thermo Fisher Scientific by 34.1% in the first quarter. Wilkerson Advisory Group LLC now owns 110 shares of the medical research company’s stock worth $54,000 after purchasing an additional 28 shares during the last quarter. Finally, Glenview Trust Co increased its position in Thermo Fisher Scientific by 0.5% in the first quarter. Glenview Trust Co now owns 24,324 shares of the medical research company’s stock worth $11,956,000 after purchasing an additional 110 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Erste Group raised its FY2027 earnings estimate for Thermo Fisher, signaling slightly better long-term profit expectations for the company. Article
• Positive Sentiment: Thermo Fisher was included in CNBC’s “Final Trades,” which can reinforce investor interest and visibility in the stock. Article
• Neutral Sentiment: Thermo Fisher continues to be viewed as a key player in life sciences tools, and a new market note questioned whether the recent pullback makes the shares more attractive from a valuation standpoint. Article
• Neutral Sentiment: Proscia’s MedTech Breakthrough Award win mentioned Thermo Fisher among industry peers, but the item was focused on Proscia rather than a direct company-specific catalyst for TMO. Article
• Negative Sentiment: Wells Fargo cut its price target on Thermo Fisher from $675 to $615, which can weigh on sentiment even though the firm kept an overweight rating. Article

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.